Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 9/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.34 |
| ▸ | HTR3B | O95264 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.34 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.34 |
| ▸ | MPL | P40238 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29648906 | 1.00 | MAPK1 (0.44) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL6895856 | 0.85 | ALDH1A1 (0.43) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL4462791 | 0.85 | KIF11 (0.45) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL30196175 | 0.85 | KIF11 (0.45) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL1555041 | 0.85 | MAPK1 (0.47) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL7177146 | 0.83 | MAPK1 (0.46) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL30673506 | 0.81 | P2RY6 (0.38) | TDP1CYP3A4ARIDO1HTR3E | |
| SCHEMBL3104369 | 0.81 | CYP3A4 (0.50) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL1435515 | 0.81 | P2RY6 (0.38) | TDP1CYP3A4ARIDO1HTR3E | |
| SCHEMBL28113838 | 0.81 | TRPA1 (0.35) | MAPK1TDP1CYP3A4TRPA1SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 361 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118016995-A | Non-aqueous electrolyte containing aromatic isocyanate and lithium ion battery | 诺莱特电池材料(苏州)有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-112795299-A | Antireflection coating liquid, preparation method thereof and solar cell module | 中建材（合肥）新能源有限公司 | 2021-05-14 | — | — | CN | claimed |
| CN-110499077-A | A kind of non-stick pan coating layer of high-strength, high-anti-friction | Ningbo xiermei kitchenware co ltd | 2019-11-26 | — | — | CN | claimed |
| EP-3261631-B1 | INHIBITION OF OLIG2 ACTIVITY | CURTANA PHARMACEUTICALS INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12312334-B2 | Quinoxaline compounds and uses thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2025-05-27 | — | — | US | disclosed |
| EP-3774961-B1 | ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2025-01-15 | — | — | EP | disclosed |
| CN-113923988-B | Substituted arylmethyl ureas and heteroarylmethyl ureas, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-4464727-A1 | ESTERIFIED ETHANOLAMINES FOR THE PREPARATION OF ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2024-11-20 | — | — | EP | disclosed |
| CN-113262218-B | Use of isothiocyanate compounds | 无锡杰西医药股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-118016995-A | Non-aqueous electrolyte containing aromatic isocyanate and lithium ion battery | 诺莱特电池材料(苏州)有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20240150515-A1 | Low Viscosity Catalyst Compositions for Producing Isocyanurate Polymers | COVESTRO DEUTSCHLAND AG (DE) | 2024-05-09 | — | — | US | disclosed |
| WO-2003062206-A2 | SMALL MOLECULE MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003047568-A1 | N-ARYL-N'-ARYLCYCLOALKYL-UREA DERIVATIVES AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY | SCHERING CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
| US-20030105094-A1 | MCH antagonists and their use in the treatment of obesity | SCHERING CORPORATION | 2003-06-05 | — | — | US | disclosed |
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
| US-20030022891-A1 | MCH antagonists and their use in the treatment of obesity | SCHERING CORPORATION | 2003-01-30 | — | — | US | disclosed |
| WO-2002076947-A1 | MCH ANTAGONISTS AND THEIR USE IN THE TREATMENT OF OBESITY | SCHERING CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
| WO-2002060900-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| WO-2002057233-A1 | MCH ANTAGONISTS AND THEIR USE IN THE TREATMENT OF OBESITY | SCHERING CORPORATION (US) | 2002-07-25 | — | — | WO | disclosed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312334-B2 | Quinoxaline compounds and uses thereof | NFKBIA, RELA, IKBKB | MAPK1 511/4885TDP1 1119/4885CYP3A4 3189/4885 |
| US-20030105094-A1 | MCH antagonists and their use in the treatment of obesity | MCHR1, MCHR2, MC4R | MAPK1 2671/4885TDP1 4451/4885CYP3A4 2614/4885 |
| US-20030022891-A1 | MCH antagonists and their use in the treatment of obesity | MCHR1, MCHR2, MC4R | MAPK1 1470/4885TDP1 4656/4885CYP3A4 2250/4885 |
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | MAPK1 393/4885TDP1 3889/4885CYP3A4 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.